Drug survival and predictor factors for discontinuation of first-line biologic therapy in rheumatoid arthritis: data from a real-world single-centre study
Main finding · Events (discontinuation due to inefficacy or AE)Result — go to the resultIncidence rate ratio 0.52 95% CI 0.27–0.92Authors' conclusion
Only 26.7% of patients remained on first bDMARD after 50 months, with those receiving RTX less likely to discontinue for any reason.
Study context
- Population
- Patients with rheumatoid arthritis (RA) receiving their first biological disease-modifying anti-rheumatic drug (bDMARD), Pathophysiology Clinic of LAIKON University Hospital, Greece; 79% female, baseline DAS28-ESR 4.9 ±1.5
- Participants
- 724 patients
- Exposure
- First-line anti-tumour necrosis factor (anti-TNF) vs non-anti-TNF bDMARD
- Rituximab (RTX)n = 40
- Outcome
- Drug survival of first bDMARD; event = discontinuation due to inefficacy or AE, including severe infections
Methodological detailssingle-centre, real-world, Kaplan-Meier, Cox proportional hazards
- Single-centre
- Real-world
- Kaplan-Meier
- Cox proportional hazards
Main finding
Events:
Incidence rate ratio
0.52
95% CI 0.27–0.92
RTXvs anti-TNF
IRR 0.52 (95% CI 0.27–0.92)
As reported in the abstract
- Remained on first bDMARD after 50 months
- 26.7%
- Withdrawals within the first 50 months regardless of cause
- 73.3%
Observational data: associations, not effects.
Further findings
Reasons for discontinuation · 276 months
- Discontinued due to inefficacy
- 223
- Discontinued due to adverse event (AEs)
- 187
Predictors of discontinuation
- RTX protective against treatment failure
- RF and ACPA positivity potential risk factors for discontinuation due to failure or AE
Original publication
Drug survival and predictor factors for discontinuation of first-line biologic therapy in rheumatoid arthritis: data from a real-world single-centre study. Clin Exp Rheumatol. Published 5 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →